Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalised anxiety disorder in the United Kingdom

被引：12

作者：

Guest J.F. ^{[1
,2
]}

Russ J. ^{[1
]}

Lenox-Smith A. ^{[2
]}

机构：

[1] Wyeth Laboratories, Maidenhead

[2] Catalyst Health Economics Consultants, Northwood

来源：

The European Journal of Health Economics | 2005年 / 6卷 / 2期

关键词：

Anxiety; Costs; Diazepam; National Health Service; Venlafaxine;

D O I：

10.1007/s10198-004-0272-z

中图分类号：

学科分类号：

摘要：

This study used decision modelling to compare the cost-effectiveness of venlafaxine XL (Efexor XL) to that of diazepam to treat non-depressed patients suffering from generalised anxiety disorder (GAD), from the perspective of the United Kingdom's National Health Service (NHS). Starting treatment with venlafaxine XL instead of diazepam significantly increased the expected probability of being in remission by 83% at 6 months (from 16.8% to 30.7%), and the expected probability of relapsing at 6 months was decreased by 79% (from 16.9% to 3.5%). The expected 6-month NHS cost of using venlafaxine XL to treat GAD was estimated to be £353 compared to £311 with diazepam. Hence starting GAD treatment with venlafaxine XL (75 mg per day) instead of diazepam (5 mg three times per day) is clinically more effective and the cost-effective strategy for managing non-depressed patients suffering from GAD in the UK. © Springer Medizin Verlag 2005.

引用

页码：136 / 145

页数：9

共 28 条

[1] Diagnostic and Statistical Manual of Mental Disorders, 4th Edn, Text Revision (DSM-IV-TR), (2000)
[2] Jenkins R., Lewis G., Bebbington P., Et al., The national psychiatric morbidity surveys of Great Britain - Initial findings from the household survey, Psychol Med, 27, pp. 775-789, (1997)
[3] Kessler R.C., McGonagle K.A., Zhao S., Et al., Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States, Arch Gen Psychiatry, 51, pp. 8-19, (1994)
[4] Wittchen H.-U., Zhao S., Kessler R.C., Et al., DSM-III-R generalised anxiety disorder in the national co-morbidity survey, Arch Gen Psychiatry, 51, pp. 355-364, (1994)
[5] Roerig J.L., Diagnosis and management of generalised anxiety disorder, J Am Pharm Assoc, 39, pp. 811-821, (1999)
[6] Gelenberg A.J., Lydiard R.B., Rudolph R.L., Et al., Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalised anxiety disorder: A 6-month randomized controlled trial, JAMA, 283, pp. 3082-3088, (2000)
[7] Davidson J., DuPont R., Hedges D., Et al., Efficacy, safety and tolerability of venlafaxine extended release and buspirone in outpatients with generalised anxiety disorder, J Clin Psychiatry, 60, pp. 528-535, (1999)
[8] Rickels K., Pollack M.H., Sheehan D.V., Et al., Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder, Am J Psychiatry, 157, pp. 968-974, (2000)
[9] Allgulander C., Hackett D., Salinas E., Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder, Br J Psychiatry, 179, pp. 15-22, (2001)
[10] Papp L.A., Gorman J.M., Generalised anxiety disorder, Comprehensive Textbook of Psychiatry, 6th Edn., pp. 1236-1249, (1995)

← 1 2 3 →